Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

82 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Therapies and outcomes following extramedullary relapse of pediatric and young adult ALL after CD19 CAR T-cell therapy.
Friedes BD, DiNofia AM, Iannone E, Li Y, Rheingold SR, Barz Leahy A, Wray L, Callahan C, Baniewicz D, Vernau L, Getz KD, Aplenc R, Maude SL, Grupp SA, Myers RM. Friedes BD, et al. Among authors: maude sl. Blood Adv. 2024 Nov 20:bloodadvances.2024014518. doi: 10.1182/bloodadvances.2024014518. Online ahead of print. Blood Adv. 2024. PMID: 39565957 No abstract available.
CAR T-cell therapy is effective for CD19-dim B-lymphoblastic leukemia but is impacted by prior blinatumomab therapy.
Pillai V, Muralidharan K, Meng W, Bagashev A, Oldridge DA, Rosenthal J, Van Arnam J, Melenhorst JJ, Mohan D, DiNofia AM, Luo M, Cherian S, Fromm JR, Wertheim G, Thomas-Tikhonenko A, Paessler M, June CH, Luning Prak ET, Bhoj VG, Grupp SA, Maude SL, Rheingold SR. Pillai V, et al. Among authors: maude sl. Blood Adv. 2019 Nov 26;3(22):3539-3549. doi: 10.1182/bloodadvances.2019000692. Blood Adv. 2019. PMID: 31738832 Free PMC article.
Impact of poverty and neighborhood opportunity on outcomes for children treated with CD19-directed CAR T-cell therapy.
Newman H, Li Y, Liu H, Myers RM, Tam V, DiNofia A, Wray L, Rheingold SR, Callahan C, White C, Baniewicz D, Winestone LE, Kadauke S, Diorio C, June CH, Getz KD, Aplenc R, Teachey DT, Maude SL, Grupp SA, Bona K, Leahy AB. Newman H, et al. Among authors: maude sl. Blood. 2023 Feb 9;141(6):609-619. doi: 10.1182/blood.2022017866. Blood. 2023. PMID: 36351239 Free PMC article.
Reinfusion of CD19 CAR T cells for relapse prevention and treatment in children with acute lymphoblastic leukemia.
Myers RM, Devine K, Li Y, Lawrence S, Leahy AB, Liu H, Vernau L, Callahan C, Baniewicz D, Kadauke S, McGuire R, Wertheim GB, Kulikovskaya I, Gonzalez VE, Fraietta JA, DiNofia AM, Hunger SP, Rheingold SR, Aplenc R, June CH, Grupp SA, Wray L, Maude SL. Myers RM, et al. Among authors: maude sl. Blood Adv. 2024 May 14;8(9):2182-2192. doi: 10.1182/bloodadvances.2024012885. Blood Adv. 2024. PMID: 38386999 Free PMC article.
CAR T cell viability release testing and clinical outcomes: is there a lower limit?
Chong EA, Levine BL, Grupp SA, Davis MM, Siegel DL, Maude SL, Gladney WL, Frey NV, Porter DL, Hwang WT, Chong ER, June CH, Schuster SJ. Chong EA, et al. Among authors: maude sl. Blood. 2019 Nov 21;134(21):1873-1875. doi: 10.1182/blood.2019002258. Blood. 2019. PMID: 31554634 Free PMC article. No abstract available.
82 results